XCUR
HEALTHCAREExicure Inc
AI Insight
What's Moving XCUR Today?
No stock-specific AI insight has been generated for XCUR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.71$9.50
$2.66
Fundamentals
Market Cap$17M
P/E Ratio—
EPS$-1.65
Dividend Yield—
Dividend / Share—
ROE-145.2%
Profit Margin—
Debt / Equity—
Trading
Volume27K
Avg Volume (10D)—
Shares Outstanding6.4M
XCUR News
15 articles- Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementYahoo Finance·Jun 10, 2026
- Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QYahoo Finance·Jun 1, 2026
- Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)GlobeNewswire Inc.·Apr 22, 2026
- Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsYahoo Finance·Apr 2, 2026
- Exicure, Inc. Reports Full Year 2025 Financial ResultsYahoo Finance·Mar 25, 2026
- Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantYahoo Finance·Feb 5, 2026
- Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsYahoo Finance·Jan 21, 2026
- Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual MeetingYahoo Finance·Dec 8, 2025
- Exicure, Inc. Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 7, 2025
- New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual MeetingYahoo Finance·Nov 3, 2025
- Exicure Highlights Recent Achievements and Near-term Strategic PrioritiesYahoo Finance·Oct 6, 2025
- Exicure, Inc. Reports Second Quarter 2025 Financial ResultsYahoo Finance·Aug 8, 2025
- Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsYahoo Finance·Aug 4, 2025
- Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantYahoo Finance·Aug 1, 2025
- Exicure, Inc. Reports First Quarter 2025 Financial ResultsYahoo Finance·Jun 27, 2025
All 15 articles loaded
Price Data
Open$2.96
Previous Close$2.73
Day High$2.99
Day Low$2.66
52 Week High$9.50
52 Week Low$1.71
52-Week Range
$1.71$9.50
$2.66
Fundamentals
Market Cap$17M
P/E Ratio—
EPS$-1.65
Dividend Yield—
Dividend / Share—
ROE-145.2%
Profit Margin—
Debt / Equity—
Trading
Volume27K
Avg Volume (10D)—
Shares Outstanding6.4M
About Exicure Inc
Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—